The global ELISA analyzer market size was valued at USD 567.88 million in 2022 and is expected to expand at a compound annual growth rate (CAGR) of 3.7% from 2023 to 2030. ELISA (Enzyme-linked Immunosorbent Assay) analyzers is a widely used diagnostic tool that allows for detecting and measuring specific proteins and antibodies in a sample. Increasing use of ELISA technology in clinical applications and non-clinical applications such as new drug development, vaccine development, drug monitoring, and others are expected to drive market growth over the forecast period. Moreover, the increasing introduction of technologically advanced analyzers and tests is further anticipated to increase the adoption of these products for different end-use applications.
ELISA analyzers come in different types, including benchtop and microplate readers, and can be customized to suit specific requirements. With the advancement in technology, the introduction of portable devices is increasing and making this technology more accessible to remote areas and point-of-care settings. In May 2022, Molecular Devices, LLC launched automated work cells for ELISA workflows, which streamline and automate the process of ELISA testing, allowing for faster and more efficient analysis of large volumes of samples.
The outbreak of the novel coronavirus (COVID-19) disease has increased the demand for diagnostic solutions, including ELISA analyzers, as it is considered a cornerstone in the management of the pandemic. High demand for immunoassay tests at point-of-care facilities and disease screening has increased the market growth. For instance, in January 2023, a study employed a WANTAI SARS-CoV-2 antibody ELISA kit to measure antibodies against COVID-19 in Malawi. Moreover, in response to the pandemic, several government agencies are focused on mass COVID-19 testing and are undertaking a series of initiatives for expanding analyzers, instruments, and kit volumes to boost the testing rate in their country.
The ELISA analyzers market is driven by the increasing need for advancements in technology and automation in the medical diagnostics industry. A key example of this is the strategic merger of Gold Standard Diagnostics Inc. with Novatec Immundiagnostica GmbH and Virotech Diagnostics GmbH in May 2022. It has expanded the company's product portfolio to include automated ELISA analyzers, as it is a widely used diagnostic tool that can detect and measure specific proteins and antibodies in a sample. Moreover, high demand in the diagnosis of diseases such as HIV, hepatitis, and cancer as well as in research fields such as immunology and drug development is driving the growth. Furthermore, automation in instruments is designed to provide accurate and reproducible results, further increasing the demand for these devices.
Optical filter ELISA analyzers is the fastest-growing segment, expected to grow at a CAGR of 4.3% between 2023 and 2030. The growth is attributed to the increasing participation of the players in this segment. For instance, BMG Labtech is one of the players to offer optimal filter, which is made of multi-layer substrates. Hence, increasing the number of players offering these analyzers, enhance the competitiveness of the market and further boosts the market growth of the segment.
Optical grating ELISA analyzers is estimated to capture a considerable market share in 2022. A significant number of applications of grating-type analyzers is considered to be the key growth determinant. For instance, the applications of optical grating ELISA analyzers include microbiological analysis, luciferase analysis, tyrosine kinase assay, dual luciferase analysis, Aequorin Ca2 + Analysis, Chemiluminescence analysis based ELISA, ATP Detection, DNA probes, and dsDNA analysis.
The automatic ELISA analyzers segment has captured the largest proportion of the market share in 2022 with 58.54% and is expected to maintain dominance with the fastest growth rate over the forecast period. The increase in scientific awareness is driving the demand for automated and portable ELISA analyzers, especially in developing countries. For instance, in endemic areas such as sub-Saharan Africa, portable technologies for the diagnosis of malaria, tuberculosis, West Nile virus, and other infectious diseases are vital to the mitigation of frequent disease outbreaks, which is driving the demand for novel diagnostic solutions.
Moreover, government bodies are also investing heavily to enable the adoption of the latest technologies and curb the high prevalence of various infectious diseases, such as malaria. Thus, propelling the segment growth. However, the penetration of semi-automated devices in developing countries is higher due to the cost-effectiveness of these products.
Vaccine development segment is anticipated to witness the fastest growth rate with a 4.9% CAGR from 2023 to 2030. The COVID-19 pandemic surged the development of vaccines across the globe. For instance, in April 2020, the global COVID-19 vaccine R&D included 115 vaccine candidates, out of these, around 72% of vaccines were developed by private players and 28% were developed as collaborative projects led by the academic, public sector, and other nonprofit organizations. Most of the vaccine development activities were conducted in the North American region with 46% of developers, while 18% of developers were from China, 18% in Asia (excluding China) & Australia, and 18% in Europe.
Immunology is expected to have the largest proportion of the market share in 2022. The increasing R&D investment in immunology-based research is likely to support the growth of the segment during the projected period. For instance, in February 2023, La Jolla Institute for Immunology received funding of USD 17 million from the National Institute of Allergy and Infectious Diseases to develop a data center for human immunology that can assist in immunoprofiling.
The diagnostic laboratories segment is expected to have the largest market share in 2022 with 42.72%. The largest market share of the segment can be attributed to several advantages, such as they provide fast results (approximately 3-4 hours) with highly sensitive, specific, scalable, cost-effective, and facilitating testing of various types of samples. Increasing inclination toward diagnostic laboratories for gaining fast and cost-effective testing services is expected to be a primary factor driving the demand for ELISA-based solutions, thus boosting segment growth.
Similarly, the Contract Research Organizations (CROs) segment is projected to experience the fastest CAGR during the forecast period. Key companies engage in outsourcing their research & drug development activities to various CROs to obtain a higher profit margin, which is likely to expand their scope of growth over the forecast period. Increasing preference for CROs is a consequence of their associated benefits, which include increased efficiency, cost advantages, enhanced productivity, and a higher focus on core development areas that are critical to a company’s growth.
North America accounted for the largest share of the ELISA analyzers market in 2022 with 40.50%. The growth in this region can primarily be attributed to the high adoption of technologically advanced ELISA products, favorable reimbursement scenario, and an increase in the prevalence of chronic & infectious diseases. Moreover, the ongoing global pandemic has further propelled the growth of the ELISA analyzers market. High rate of screening tests for COVID-19 and the increasing adoption of immunoassay tests at POC facilities and central labs are some of the key factors that increased the market growth.
Asia Pacific is also witnessing significant growth in the ELISA analyzers market, driven by increasing investments in research and development and the rising prevalence of chronic diseases. For instance, in February 2023, a research team from IIT Delhi developed a COVID-19 vaccine with the assistance of ELISA products to measure antigens, antibodies, or proteins. Hence, the use of ELISA in numerous research is anticipated to enhance the demand for analyzers in the region.
The global ELISA analyzers market is highly competitive, with a large number of players operating in space. These companies have a strong presence in the market, extensive product portfolios, broad geographic reach, and strong distribution networks. Additionally, many of these companies have invested heavily in research & development to stay ahead of the competition and offer their customers the most advanced and innovative ELISA analyzers. Some of the key players in the global ELISA analyzers market include:
Thermo Fisher Scientific
Abcam
Bio-Rad Laboratories
Merck KGaA
F. Hoffmann-La Roche Ltd.
Danaher Corporation
BioTech
Agilent Technologies
QIAGEN
PerkinElmer Inc.
Report Attribute |
Details |
Market size value in 2023 |
USD 583.46 million |
Revenue forecast in 2030 |
USD 754.38 million |
Growth rate |
CAGR of 3.7% from 2023 to 2030 |
Base year for estimation |
2022 |
Historical data |
2018 - 2021 |
Forecast period |
2023 - 2030 |
Quantitative units |
Revenue in USD million and CAGR from 2023 to 2030 |
Report coverage |
Revenue forecast, company ranking, competitive landscape, growth factors, and trends |
Segments covered |
Type, mode, application, end-user, region |
Regional scope |
North America; Europe; Asia Pacific; Latin America; MEA |
Country scope |
U.S.; Canada; Germany; U.K.; France; Italy; Spain; Denmark; Sweden; Norway; China; Japan; India; South Korea; Australia; Thailand; Brazil; Mexico, Argentina; South Africa; Saudi Arabia, UAE; Kuwait |
Key companies profiled |
Thermo Fisher Scientific; Abcam; Bio-Rad Laboratories; Merck KGaA; F. Hoffmann-La Roche Ltd; Danaher Corporation; BioTech; Agilent Technologies; QIAGEN; PerkinElmer Inc. |
Customization scope |
Free report customization (equivalent up to 8 analyst’s working days) with purchase. Addition or alteration to country, regional & segment scope. |
Pricing and purchase options |
Avail customized purchase options to meet your exact research needs. Explore purchase options |
This report forecasts revenue growth and provides an analysis of the latest trends in each of the sub-segments from 2018 to 2030. For this report, grand view research has segmented the global ELISA analyzers market report based on type, mode, application, end-user, and region:
Type Scope Outlook (Revenue, USD Million, 2018 - 2030)
Optical Filter ELISA Analyzer
Optical Grating ELISA Analyzers
Mode Scope Outlook (Revenue, USD Million, 2018 - 2030)
Automated ELISA Analyzers
Semi-Automated ELISA Analyzers
Application Scope Outlook (Revenue, USD Million, 2018 - 2030)
Immunology
Vaccine development
Drug Monitoring
Others
End-user Scope Outlook (Revenue, USD Million, 2018 - 2030)
Biotechnology Companies
Pharmaceutical Companies
Contract Research Organization
Diagnostic Laboratories
Regional Outlook (Revenue, USD Million, 2018 - 2030)
North America
U.S.
Canada
Europe
Germany
U.K.
France
Italy
Spain
Denmark
Sweden
Norway
Asia Pacific
China
Japan
India
South Korea
Australia
Thailand
Latin America
Brazil
Mexico
Argentina
Middle East & Africa
South Africa
Saudi Arabia
UAE
Kuwait
b. The global ELISA analyzers market is expected to grow at a compound annual growth rate of 3.7% from 2023 to 2030 and is expected to reach USD 754.38 million by 2030.
b. The automated ELISA analyzers segment is expected to dominate the ELISA Analyzers market with a share of 58.54% in 2022 due to the increasing adoption of technological advanced analyzers, increasing prevalence of targeted diseases, and government initiatives to increase the penetration of novel ELISA analyzers to improve healthcare facilities.
b. Some key players operating in the ELISA analyzers market include Thermo Fisher Scientific Inc., Abcam plc., Bio-Rad Laboratories, F. Hoffmann-La Roche Ltd, Danaher, Agilent Technologies, PerkinElmer Inc., and DiaSorin S.p.A. among others.
b. Increasing use of ELISA technology in clinical and non-clinical applications and introduction of technological advanced analyzers are the major factors driving the ELISA Analyzers market growth over the forecast period.
b. North America held the largest market share of 40.50% in 2022 and is expected to register a lucrative growth rate over the forecast period. It is attributable to the high adoption of technologically advanced ELISA analyzers, favorable reimbursement scenario, increasing usage of ELISA for diagnosis of chronic and infectious diseases in the region.
b. The global ELISA analyzers market size was estimated at USD 567.88 million in 2022 and is expected to reach USD 583.46 million in 2023.
NEED A CUSTOM REPORT?
We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities. Contact us now
We are GDPR and CCPA compliant! Your transaction & personal information is safe and secure. For more details, please read our privacy policy.
"The quality of research they have done for us has been excellent."